Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Immunogenicity, Efficacy and Safety of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia a: Interim Results from an Open-Label Multicenter Clinical Trial

Robert F. Sidonio, Jr., Christine Knoll, Flora Peyvandi, Oleksandra Stasyshyn, Ali Bulent Antmen, Seoh Leng Yeoh, Darintr Sosothikul, Caterina Maggiore, Werner Engl, Geoffrey Allen, Srilatha Tangada

Blood (2021) 138 (Supplement 1): 3184.

https://doi.org/10.1182/blood-2021-146126

Published: 2021

Journal Articles

Rurioctocog Alfa Pegol Use in Immune Tolerance Induction: Interim Results from an Open-Label Multicenter Clinical Trial in Previously Untreated Patients with Severe Hemophilia a

Robert F. Sidonio, Jr., Alexis A. Thompson, Flora Peyvandi, Canan Albayrak, Seoh Leng Yeoh, Joyce Lam, Caterina Maggiore, Werner Engl, Geoffrey Allen, Srilatha Tangada

Blood (2021) 138 (Supplement 1): 3185.

https://doi.org/10.1182/blood-2021-146143

Published: 2021

Journal Articles

Long-Term Safety and Efficacy of rFVIIIFc in Adults and Adolescents with Severe Hemophilia A: A Longitudinal Analysis of A-LONG and ASPIRE

K John Pasi, David J Perry, Johnny Mahlangu, Barbara A Konkle, MD, Savita Rangarajan, Simon Brown, Hideji Hanabusa, Shannon Jackson, Ingrid Pabinger, Lynda M Cristiano, Yingwen Dong, Elisa Tsao, Glenn F Pierce, Geoffrey Allen

Blood (2015) 126 (23): 1087.

https://doi.org/10.1182/blood.V126.23.1087.1087

Published: 2015

Journal Articles

Extended-Interval Prophylaxis with rFIXFc in Adults and Adolescents with Hemophilia B: Interim Results of the B-YOND Extension Study

Johnny Mahlangu, Amy D Shapiro, MD, K John Pasi, Margaret V Ragni, Margareth Castro Ozelo, MD PhD, Johannes Oldenburg, Tadashi Matsushita, MD PhD, Ross I Baker, MD, Huixing Yuan, Alejandra Ramirez-Santiago, Glenn F Pierce, Geoffrey Allen, Baisong Mei

Blood (2015) 126 (23): 1088.

https://doi.org/10.1182/blood.V126.23.1088.1088

Published: 2015

Journal Articles

Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies

Doris V. Quon, Robert Klamroth, Roshni Kulkarni, Amy D Shapiro, MD, Ross I Baker, MD, Giancarlo Castaman, Bryce A. Kerlin, Elisa Tsao, Geoffrey Allen

Blood (2015) 126 (23): 3543.

https://doi.org/10.1182/blood.V126.23.3543.3543

Published: 2015

Journal Articles

Long-Term Efficacy of rFVIIIFc Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia A

Bryce A. Kerlin, Roshni Kulkarni, Beatrice Nolan, Michael Wang, MD, K John Pasi, Raina Liesner, Simon Brown, Hideji Hanabusa, Ingrid Pabinger-Fasching, Elisa Tsao, Geoffrey Allen

Blood (2015) 126 (23): 3520.

https://doi.org/10.1182/blood.V126.23.3520.3520

Published: 2015

Journal Articles

Predicting FVIII Activity in Patients Who Use Recombinant FVIII Fc Fusion Protein for Prophylaxis and Treatment of Bleeding Episodes

Doris V. Quon, MD PhD, Johnny N. Mahlangu, MBBCh, MMed, FCPath, Amy D Shapiro, John Pasi, MBChB, PhD FRCP, FRCPath, Ying Zhu, MPH, Glenn F Pierce, MD PhD, Lian Li, PhD, Geoffrey Allen, MD

Blood (2014) 124 (21): 1522.

https://doi.org/10.1182/blood.V124.21.1522.1522

Published: 2014

Journal Articles

Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study

Amy Shapiro, MD, John Pasi, MBChB, PhD, FRCP, FRCPath, Johnny Mahlangu, MD, David J. Perry, MD, PhD, FRCP, FRCPath, Jerry S Powell, MD, Margaret V. Ragni, MD, MPH, Leonard A. Valentino, MD, FAAP, Margareth Ozelo, MD, PhD, Karen Nugent, MSc, Shuanglian Li, MD, PhD, Aoife Brennan, MB, BCh, BAO, MMSC, Glenn F Pierce, MD, PhD, Geoffrey Allen, MD

Blood (2013) 122 (21): 2350.

https://doi.org/10.1182/blood.V122.21.2350.2350

Published: 2013

Journal Articles

Pharmacokinetics Of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Pediatric Subjects With Hemophilia A: An Interim Analysis Of The Kids A-LONG Study

Guy Young, MD, Johnny Mahlangu, MD, Beatrice Nolan, MB, MRCPI, FRCPATH, Simon Brown, MD, FRACP, FRCPA, MBBS, FRCP, FRCPath, Leonard A. Valentino, MD, FAAP, Raina Liesner, MA, MBBChir, MD, FRCP, FRCPath, MRCPCH, Yingwen Dong, PhD, Lei Diao, PhD, Haiyan Jiang, PhD, Karen Nugent, MSc, Glenn F. Pierce, MD, PhD, Geoffrey Allen, MD

Blood (2013) 122 (21): 3609.

https://doi.org/10.1182/blood.V122.21.3609.3609

Published: 2013

Journal Articles

Pharmacokinetics Of Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Pediatric Subjects With Hemophilia B: An Interim Analysis Of The Kids B-LONG Study

Kathelijn Fischer, MD, PhD, Roshni Kulkarni, MD, Myles Bradbury, MD, Margaret V. Ragni, MD, MPH, Savita Rangarajan, MBBS, FRCP, FRCPath, Yingwen Dong, PhD, Shuanglian Li, MD, PhD, Haiyan Jiang, PhD, Karen Nugent, MSc, Glenn F Pierce, MD, PhD, Geoffrey Allen, MD

Blood (2013) 122 (21): 3599.

https://doi.org/10.1182/blood.V122.21.3599.3599

Published: 2013

NARROW

Immunogenicity, Efficacy and Safety of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia a: Interim Results from an Open-Label Multicenter Clinical Trial

Rurioctocog Alfa Pegol Use in Immune Tolerance Induction: Interim Results from an Open-Label Multicenter Clinical Trial in Previously Untreated Patients with Severe Hemophilia a

Long-Term Safety and Efficacy of rFVIIIFc in Adults and Adolescents with Severe Hemophilia A: A Longitudinal Analysis of A-LONG and ASPIRE

Extended-Interval Prophylaxis with rFIXFc in Adults and Adolescents with Hemophilia B: Interim Results of the B-YOND Extension Study

Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies

Long-Term Efficacy of rFVIIIFc Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia A

Predicting FVIII Activity in Patients Who Use Recombinant FVIII Fc Fusion Protein for Prophylaxis and Treatment of Bleeding Episodes

Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study

Pharmacokinetics Of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Pediatric Subjects With Hemophilia A: An Interim Analysis Of The Kids A-LONG Study

Pharmacokinetics Of Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Pediatric Subjects With Hemophilia B: An Interim Analysis Of The Kids B-LONG Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only